Name: 글로벌 시장 동향
SKU: PH2649
Availability: InStock

보고서 요약(국문)

보고서 개요
글로벌 올리고뉴클레오티드 합성 시장은 2023년 75억 달러 규모에 도달했으며, 2024년부터 2031년까지 연평균 9.0%의 성장률을 기록하며 2031년에는 152억 달러에 이를 것으로 예상됩니다.
올리고뉴클레오티드 합성은 분자 생물학, 생명 공학 및 치료 분야에 사용되는 올리고뉴클레오티드라고 하는 짧은 뉴클레오티드 서열을 생성하는 화학적 공정입니다. 이러한 합성 DNA 또는 RNA 가닥은 유전자 분석, 진단 및 치료에 사용됩니다. 이 기술의 발전으로 맞춤형 의학, RNA 기반 백신 및 유전 질환에 대한 표적 치료법이 가능해졌습니다. 합성 올리고뉴클레오티드 시장은 유전체학, 바이오 의약품 및 진단 분야의 혁신으로 인해 지속적으로 확대되고 있습니다.
시장 동향: 동인 및 제약 요인
제약 및 생명 공학 기업에 대한 투자 증가
정부 자금 및 연구 개발에 대한 상당한 투자가 혁신과 치료법 탐색을 촉진하면서 올리고뉴클레오티드 합성 시장이 성장하고 있습니다. 하지만 비용 하락과 표준화된 가이드라인 부족과 같은 문제점들이 잠재적인 걸림돌로 작용할 수 있습니다. 따라서 이해관계자들은 이러한 시장 역학을 잘 파악하여 가까운 미래에 시장의 성장 잠재력을 최대한 활용해야 합니다.
예를 들어, 2024년 6월 GSK plc는 올리고뉴클레오티드 치료제의 잠재력을 극대화하는 데 전념하는 샌디에이고 소재 비상장 생명공학 회사인 Elsie Biotechnologies를 최대 5천만 달러(약 3천9백만 파운드)에 인수했다고 발표했습니다. 올리고뉴클레오티드는 유전자 발현을 조절하는 독특한 능력을 가지고 있어 기존의 소분자나 생물학적 제제로는 치료가 어려운 상당수의 치료 표적을 공략할 수 있는 매력적인 치료법입니다.
비용 하락
올리고뉴클레오티드 합성 시장은 비용 하락, 치료용 올리고 가이드라인의 불확실성, 그리고 통일된 가이드라인 부족으로 인해 어려움을 겪고 있습니다. 이러한 요인들은 수익 마진과 시장 지속 가능성에 영향을 미쳐 올리고뉴클레오티드 합성 기술의 원활한 발전을 저해할 수 있습니다. 분자 진단 및 임상 응용 분야에서 지속적인 성장을 위해서는 업계 이해관계자들이 이러한 문제들을 효과적으로 해결하는 것이 중요합니다.

시장 세분화 분석
글로벌 올리고뉴클레오티드 합성 시장은 제품 유형, 응용 분야, 최종 사용자 및 지역별로 세분화됩니다.
제품 유형 부문에서 시약은 올리고뉴클레오티드 합성 시장 점유율의 약 41.3%를 차지했습니다.
글로벌 올리고뉴클레오티드 합성 시장은 포스포라미다이트, 용매, 촉매 및 캡핑제와 같은 시약에 크게 의존하며, 이러한 시약은 합성 공정의 효율성, 정확성 및 수율을 좌우합니다. 고품질 시약은 올리고뉴클레오티드 사슬의 정확성을 보장하고 오류를 최소화합니다. 유전자 편집, 진단 및 치료 분야에서 정밀하고 신뢰할 수 있는 올리고뉴클레오티드에 대한 수요 증가로 인해 합성 시약 시장은 크게 성장했습니다. 올리고뉴클레오티드 기반 연구의 성공과 새로운 치료제 개발은 시약 품질 향상과 직접적으로 연관되어 있습니다.

예를 들어, 2024년 9월 Emp Biotech는 Atom Scientific와 제휴하여 영국과 아일랜드에 자사의 고품질 올리고뉴클레오티드 합성 시약을 유통하기로 했으며, 이는 해당 회사의 올리고뉴클레오티드 합성 제품에 대한 독점 유통 파트너십을 의미합니다.
시장 지역별 점유율
북미는 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다.
북미는 생명 과학 및 의료 분야의 연구 개발 투자 증가와 다양한 질병에 대한 맞춤형 치료법 개발에 대한 관심 증대로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다.
예를 들어, 2024년 5월, 선도적인 효소 엔지니어링 회사인 Codexis, Inc.는 RNA 기반 치료제 제조를 지원하기 위해 효소 경로를 통해 올리고뉴클레오티드를 성공적으로 합성했다고 발표했습니다. 코덱시스(Codexis)는 출발 물질로부터 접합 부위를 부착하는 효소적 합성을 통해 전장 올리고뉴클레오티드를 최초로 합성하는 데 성공했으며, 이는 RNAi 치료제 산업에서 새로운 제조 방법을 위한 중요한 공정 검증 사례입니다.
또한, 미국 암 협회(American Cancer Society)는 2024년에 미국에서 2,001,140건의 새로운 암 발병 사례와 611,720건의 암 관련 사망 사례가 발생할 것으로 예측하고 있습니다. 새롭고 개선된 암 치료법에 대한 수요가 증가함에 따라 합성 올리고뉴클레오티드에 대한 필요성도 커지고 있습니다. 합성 올리고뉴클레오티드는 다양한 연구 및 진단 분야에 사용됩니다.

시장 세분화
제품 유형별
시약
장비
합성 올리고뉴클레오티드
올리고뉴클레오티드 기반 의약품
프라이머
프로브
대규모 합성 올리고뉴클레오티드
기타
응용 분야별
연구
PCR
QPCR
시퀀싱
유전자 합성
기타
진단
치료
DNA 및 올리고뉴클레오티드 기반 치료제
RNAi 올리고뉴클레오티드 기반 치료제
CpG 올리고뉴클레오티드 기반 치료제
최종 사용자별
병원
학술 및 연구 기관
제약 및 생명공학 회사
진단 연구소
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
이탈리아
스페인
기타 유럽
남미
브라질
아르헨티나
기타 남미 미국
아시아 태평양
중국
인도
일본
한국
기타 아시아 태평양 지역
중동 및 아프리카
시장 경쟁 구도
주요 글로벌 시장 참여 기업으로는 Thermo Fisher Scientific Inc., Agilent Technologies Inc., Integrated DNA Technologies (IDT), LGC Biosearch Technologies, Bio-Synthesis Inc., GE Healthcare (Cytiva), Eurofins Genomics, TriLink BioTechnologies (Maravai LifeSciences 계열사), Merck KGaA (Sigma-Aldrich), ATDBio Ltd 등이 있습니다.
주요 개발 사항
효소 DNA 합성 분야의 선구자이자 리더인 Molecular Assemblies, Inc.는 2024년 5월, 현장 합성을 위한 Molecular Assemblies의 완전 효소 합성(FEST™) 기술 라이선스 파트너십 프로그램을 발표했습니다. FEST™ 기술은 길고 순수하며 정확한 DNA 생산을 가속화하여 빠르게 발전하는 차세대 치료제 및 진단법에 필요한 기술을 제공합니다.

2023년 3월, Ansa는 업계 최고 수준의 정확도로 1005개 염기 길이의 올리고뉴클레오티드를 성공적으로 합성하여 올리고뉴클레오티드 합성 분야에서 중요한 진전을 이루었습니다. 이 회사는 2023년 4월, 유전자 치료 개발에 필요한 1005개 염기 서열과 같이 매우 복잡하고 짧은 올리고뉴클레오티드의 조립이 필요한 까다로운 서열을 연구자들이 얻을 수 있도록 지원하기 위해 클론 합성 유전자 조기 접근 프로그램을 출시했습니다.

보고서 구매 이유:

제품 유형, 응용 분야, 최종 사용자 및 지역별 글로벌 올리고뉴클레오티드 합성 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴할 수 있습니다.

모든 세그먼트를 포함한 올리고뉴클레오티드 합성 시장 수준의 다양한 데이터가 담긴 엑셀 시트를 제공합니다.

심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

주요 기업의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일을 제공합니다.

글로벌 올리고뉴클레오티드 합성 시장 보고서는 약 64개의 표, 61개의 그림, 그리고 186페이지 분량으로 구성될 예정입니다.
대상 고객 (2024년 기준)
제조업체/구매자
산업 투자자/투자은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Report Overview
Global Oligonucleotide Synthesis Market reached US$ 7.5 billion in 2023 and is expected to reach US$ 15.2 billion by 2031, growing at a CAGR of 9.0% during the forecast period 2024-2031
Oligonucleotide synthesis is the chemical process of creating short nucleotide sequences, known as oligonucleotides, for molecular biology, biotechnology, and therapeutic applications. These synthetic DNA or RNA strands are used in genetic analysis, diagnostics, and therapeutics. Advancements in this technology have led to personalized medicine, RNA-based vaccines, and targeted therapies for genetic diseases. The market for synthetic oligonucleotides continues to expand due to innovations in genomics, biopharmaceuticals, and diagnostics.
Market Dynamics: Drivers & Restraints
Increased investment in pharmaceutical and biotechnology companies
The oligonucleotide synthesis market is boosted by substantial investment from government funds and research, promoting innovation and therapeutic exploration. However, challenges like cost erosion and lack of standardized guidelines pose potential hindrances. Therefore, stakeholders must navigate these market dynamics to fully capitalize on the market's growth potential in the near future.
For instance, in June 2024, GSK plc announced that it had acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for up to $50 million (approximately £39 million). Oligonucleotides have a unique ability to modulate gene expression, making them an attractive modality to address a significant proportion of therapeutic targets that are not amenable to traditional small molecules or biologics.
Erosion of costs
The oligonucleotide synthesis market faces challenges due to cost erosion, uncertainty in therapeutic oligo guidelines, and a lack of unified guidelines. These factors could impact profit margins and market sustainability, hindering the seamless progression of oligonucleotide synthesis technologies. It is crucial for industry stakeholders to effectively address these challenges for sustained growth in molecular diagnostics and clinical applications.
Market Segment Analysis
The global oligonucleotide synthesis market is segmented based on product type, application, end-user, and region.
The reagents from the product type segment accounted for approximately 41.3% of the oligonucleotide synthesis market share
The reagents from the product type segment accounted for approximately 41.3%. The global oligonucleotide synthesis market relies heavily on reagents, including phosphoramidites, solvents, catalysts, and capping agents, which control the efficiency, accuracy, and yield of the synthesis process. High-quality reagents ensure the fidelity of oligonucleotide chains and minimize errors. The market for synthesis reagents has expanded significantly due to the growing demand for precise and reliable oligonucleotides in gene editing, diagnostics, and therapeutics. The success of oligonucleotide-based research and the development of novel therapeutics are directly linked to reagent quality advancements.
For instance, in September 2024, Emp Biotech partnered with Atom Scientific to distribute its high-quality oligonucleotide synthesis reagents in the UK and Ireland, marking an exclusive distribution partnership for the company's oligonucleotide synthesis products.
Market Geographical Share
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to increasing R&D investments in the field of life sciences and healthcare and the growing focus on developing personalized therapeutics for various diseases are major factors supporting the large share of this market.
For instance, in May 2024, Codexis, Inc. a leading enzyme engineering company, announced it successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Codexis has achieved the first enzymatic synthesis of a full-length oligonucleotide from starting material through the attachment of a conjugation moiety, providing a significant proof of process for alternative manufacturing methods in the RNAi therapeutics industry.
Moreover, the American Cancer Society predicts that in the year 2024, there will be 2,001,140 new cancer cases and 611,720 cancer-related deaths in the U.S. As the demand for new and improved cancer treatments increases, the requirement for synthetic oligonucleotides is growing. The synthetic oligonucleotides are used in a variety of research and diagnostic applications.
Market Segmentation
By Product Type
Reagents
Equipment
Synthesized Oligonucleotides
Oligonucleotide-based drugs
Primers
Probes
Large-scale synthesized oligonucleotides
Others
By Application
Research
PCR
QPCR
Sequencing
Gene Synthesis
Others
Diagnostics
Therapeutics
DNA & Oligonucleotide-based therapies
RNAi Oligonucleotide-based therapies
CpG Oligonucleotide-based therapies
By End User
Hospitals
Academic & Research Institutes
Pharmaceutical & Biotechnology companies
Diagnostic Laboratories
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the market include Thermo Fisher Scientific Inc., Agilent Technologies Inc., Integrated DNA Technologies (IDT), LGC Biosearch Technologies, Bio-Synthesis Inc., GE Healthcare (Cytiva), Eurofins Genomics, TriLink BioTechnologies (a Maravai LifeSciences company), Merck KGaA (Sigma-Aldrich), ATDBio Ltd among others.
Key Developments
In May 2024, Molecular Assemblies, Inc. a pioneer and leader in the field of enzymatic DNA synthesis, announced the launch of its Partnering Program to license Molecular Assemblies’ Fully Enzymatic SynthesisTM (FESTM) technology for onsite synthesis. FES technology accelerates the production of long, pure, and accurate DNA to power a new rapidly emerging generation of therapeutics and diagnostics.
In March 2023, Ansa successfully synthesized a 1005-base-long oligonucleotide with industry-leading accuracy, marking a significant advancement in oligonucleotide synthesis. The company launched an Early Access Program for clonal synthetic genes in April 2023 to assist researchers in obtaining challenging sequences, such as the 1005 base sequence for gene therapy development, which is highly complex and requires the assembly of shorter oligonucleotides.
Why Purchase the Report?
To visualize the global oligonucleotide synthesis market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the oligonucleotide synthesis market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global oligonucleotide synthesis market report would provide approximately 64 tables, 61 figures, and 186 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increased investment in pharmaceutical and biotechnology companies
4.1.1.2. Advancements in the research and development
4.1.2. Restraints
4.1.2.1. Erosion of costs
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Product Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
6.1.2. Market Attractiveness Index, By Product Type
6.2. Reagents*
6.2.1. Introduction
6.3. Equipment
6.4. Synthesized Oligonucleotides
7. By Application
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.2. Market Attractiveness Index, By Application
7.3. Research*
7.3.1. Introduction
7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.4. Diagnostics
7.5. Therapeutics
8. By End User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Academic & Research Institutes
8.4. Pharmaceutical & Biotechnology companies
8.5. Diagnostic Laboratories
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Thermo Fisher Scientific Inc*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Agilent Technologies Inc.
11.3. Integrated DNA Technologies (IDT)
11.4. LGC Biosearch Technologies
11.5. Bio-Synthesis Inc.
11.6. GE Healthcare (Cytiva)
11.7. Eurofins Genomics
11.8. TriLink BioTechnologies (a Maravai LifeSciences company)
11.9. Merck KGaA (Sigma-Aldrich)
11.10. ATDBio Ltd. (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Thermo Fisher Scientific Inc, 4.	Key Developments, Agilent Technologies Inc., Integrated DNA Technologies (IDT), LGC Biosearch Technologies, Bio-Synthesis Inc., GE Healthcare (Cytiva), Eurofins Genomics, TriLink BioTechnologies (a Maravai LifeSciences company), Merck KGaA (Sigma-Aldrich)

표 목록 (Tables)

List of Tables

Table 1 Global Oligonucleotide Synthesis Market Value, By Product Type, 2023, 2027 & 2031 (US$ Billion)

Table 2 Global Oligonucleotide Synthesis Market Value, By Application, 2023, 2027 & 2031 (US$ Billion)

Table 3 Global Oligonucleotide Synthesis Market Value, By End User, 2023, 2027 & 2031 (US$ Billion)

Table 4 Global Oligonucleotide Synthesis Market Value, By Product Type, 2023, 2027 & 2031 (US$ Billion)

Table 5 Global Oligonucleotide Synthesis Market Value, By Product Type, 2022-2031 (US$ Billion)

Table 6 Global Oligonucleotide Synthesis Market Value, By Application, 2023, 2027 & 2031 (US$ Billion)

Table 7 Global Oligonucleotide Synthesis Market Value, By Application, 2022-2031 (US$ Billion)

Table 8 Global Oligonucleotide Synthesis Market Value, By End User, 2023, 2027 & 2031 (US$ Billion)

Table 9 Global Oligonucleotide Synthesis Market Value, By End User, 2022-2031 (US$ Billion)

Table 10 North America Oligonucleotide Synthesis Market Value, By Product Type, 2022-2031 (US$ Billion)

Table 11 North America Oligonucleotide Synthesis Market Value, By Application, 2022-2031 (US$ Billion)

Table 12 North America Oligonucleotide Synthesis Market Value, By End User, 2022-2031 (US$ Billion)

Table 13 North America Oligonucleotide Synthesis Market Value, By Region, 2022-2031 (US$ Billion)

Table 14 South America Oligonucleotide Synthesis Market Value, By Product Type, 2022-2031 (US$ Billion)

Table 15 South America Oligonucleotide Synthesis Market Value, By Application, 2022-2031 (US$ Billion)

Table 16 South America Oligonucleotide Synthesis Market Value, By End User, 2022-2031 (US$ Billion)

Table 17 South America Oligonucleotide Synthesis Market Value, By Region, 2022-2031 (US$ Billion)

Table 18 Europe Oligonucleotide Synthesis Market Value, By Product Type, 2022-2031 (US$ Billion)

Table 19 Europe Oligonucleotide Synthesis Market Value, By Application, 2022-2031 (US$ Billion)

Table 20 Europe Oligonucleotide Synthesis Market Value, By End User, 2022-2031 (US$ Billion)

Table 21 Europe Oligonucleotide Synthesis Market Value, By Region, 2022-2031 (US$ Billion)

Table 22 Asia-Pacific Oligonucleotide Synthesis Market Value, By Product Type, 2022-2031 (US$ Billion)

Table 23 Asia-Pacific Oligonucleotide Synthesis Market Value, By Application, 2022-2031 (US$ Billion)

Table 24 Asia-Pacific Oligonucleotide Synthesis Market Value, By End User, 2022-2031 (US$ Billion)

Table 25 Asia-Pacific Oligonucleotide Synthesis Market Value, By Region, 2022-2031 (US$ Billion)

Table 26 Rest of Europe Oligonucleotide Synthesis Market Value, By Product Type, 2022-2031 (US$ Billion)

Table 27 Rest of Europe Oligonucleotide Synthesis Market Value, By Application, 2022-2031 (US$ Billion)

Table 28 Rest of Europe Oligonucleotide Synthesis Market Value, By End User, 2022-2031 (US$ Billion)

Table 29 Rest of Europe Oligonucleotide Synthesis Market Value, By Region, 2022-2031 (US$ Billion)

Table 30 Thermo Fisher Scientific Inc.: Overview

Table 31 Thermo Fisher Scientific Inc.: Product Portfolio

Table 32 Thermo Fisher Scientific Inc.: Key Developments

Table 33 Agilent Technologies Inc.: Overview

Table 34 Agilent Technologies Inc.: Product Portfolio

Table 35 Agilent Technologies Inc.: Key Developments

Table 36 Integrated DNA Technologies (IDT): Overview

Table 37 Integrated DNA Technologies (IDT): Product Portfolio

Table 38 Integrated DNA Technologies (IDT): Key Developments

Table 39 LGC Biosearch Technologies: Overview

Table 40 LGC Biosearch Technologies: Product Portfolio

Table 41 LGC Biosearch Technologies: Key Developments

Table 42 Bio-Synthesis Inc.: Overview

Table 43 Bio-Synthesis Inc.: Product Portfolio

Table 44 Bio-Synthesis Inc.: Key Developments

Table 45 GE Healthcare (Cytiva): Overview

Table 46 GE Healthcare (Cytiva): Product Portfolio

Table 47 GE Healthcare (Cytiva): Key Developments

Table 48 Eurofins Genomics: Overview

Table 49 Eurofins Genomics: Product Portfolio

Table 50 Eurofins Genomics: Key Developments

Table 51 TriLink BioTechnologies (a Maravai LifeSciences company): Overview

Table 52 TriLink BioTechnologies (a Maravai LifeSciences company): Product Portfolio

Table 53 TriLink BioTechnologies (a Maravai LifeSciences company): Key Developments

Table 54 Merck KGaA (Sigma-Aldrich): Overview

Table 55 Merck KGaA (Sigma-Aldrich): Product Portfolio

Table 56 Merck KGaA (Sigma-Aldrich): Key Developments

Table 57 ATDBio Ltd.: Overview

Table 58 ATDBio Ltd.: Product Portfolio

Table 59 ATDBio Ltd.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 2 Global Oligonucleotide Synthesis Market Share, By Product Type, 2023 & 2031 (%)

Figure 3 Global Oligonucleotide Synthesis Market Share, By Application, 2023 & 2031 (%)

Figure 4 Global Oligonucleotide Synthesis Market Share, By End User, 2023 & 2031 (%)

Figure 5 Global Oligonucleotide Synthesis Market Y-o-Y Growth, By Product Type, 2023-2031 (%)

Figure 6 Reagents Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 7 Equipment Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 8 Synthesized Oligonucleotides Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 9 Global Oligonucleotide Synthesis Market Y-o-Y Growth, By Application, 2023-2031 (%)

Figure 10 Research Application in Global Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 11 Diagnostics Application in Global Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 12 Therapeutics Application in Global Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 13 Global Oligonucleotide Synthesis Market Y-o-Y Growth, By End User, 2023-2031 (%)

Figure 14 Hospitals End User in Global Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 15 Academic & Research Institutes End User in Global Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 16 Pharmaceutical & Biotechnology Companies End User in Global Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 17 Diagnostic Laboratories End User in Global Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 18 North America Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 19 North America Oligonucleotide Synthesis Market Share, By Product Type, 2023 & 2031 (%)

Figure 20 North America Oligonucleotide Synthesis Market Share, By Application, 2023 & 2031 (%)

Figure 21 North America Oligonucleotide Synthesis Market Share, By End User, 2023 & 2031 (%)

Figure 22 North America Oligonucleotide Synthesis Market Share, By Region, 2023 & 2031 (%)

Figure 23 South America Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 24 South America Oligonucleotide Synthesis Market Share, By Product Type, 2023 & 2031 (%)

Figure 25 South America Oligonucleotide Synthesis Market Share, By Application, 2023 & 2031 (%)

Figure 26 South America Oligonucleotide Synthesis Market Share, By End User, 2023 & 2031 (%)

Figure 27 South America Oligonucleotide Synthesis Market Share, By Region, 2023 & 2031 (%)

Figure 28 Europe Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 29 Europe Oligonucleotide Synthesis Market Share, By Product Type, 2023 & 2031 (%)

Figure 30 Europe Oligonucleotide Synthesis Market Share, By Application, 2023 & 2031 (%)

Figure 31 Europe Oligonucleotide Synthesis Market Share, By End User, 2023 & 2031 (%)

Figure 32 Europe Oligonucleotide Synthesis Market Share, By Region, 2023 & 2031 (%)

Figure 33 Asia-Pacific Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 34 Asia-Pacific Oligonucleotide Synthesis Market Share, By Product Type, 2023 & 2031 (%)

Figure 35 Asia-Pacific Oligonucleotide Synthesis Market Share, By Application, 2023 & 2031 (%)

Figure 36 Asia-Pacific Oligonucleotide Synthesis Market Share, By End User, 2023 & 2031 (%)

Figure 37 Asia-Pacific Oligonucleotide Synthesis Market Share, By Region, 2023 & 2031 (%)

Figure 38 Rest of Europe Oligonucleotide Synthesis Market Value, 2022-2031 (US$ Billion)

Figure 39 Rest of Europe Oligonucleotide Synthesis Market Share, By Product Type, 2023 & 2031 (%)

Figure 40 Rest of Europe Oligonucleotide Synthesis Market Share, By Application, 2023 & 2031 (%)

Figure 41 Rest of Europe Oligonucleotide Synthesis Market Share, By End User, 2023 & 2031 (%)

Figure 42 Thermo Fisher Scientific Inc.: Financials

Figure 43 Agilent Technologies Inc.: Financials

Figure 44 Integrated DNA Technologies (IDT): Financials

Figure 45 LGC Biosearch Technologies: Financials

Figure 46 Bio-Synthesis Inc.: Financials

Figure 47 GE Healthcare (Cytiva): Financials

Figure 48 Eurofins Genomics: Financials

Figure 49 TriLink BioTechnologies (a Maravai LifeSciences company): Financials

Figure 50 Merck KGaA (Sigma-Aldrich): Financials

Figure 51 ATDBio Ltd.: Financials

글로벌 올리고뉴클레오티드 합성 시장 – 2024년 – 2031년

Global Oligonucleotide Synthesis Market - 2024 - 2031